Starting Up: What's Attractive To Biotech Investors?

Industry observers maintain that capital is available for companies that have the right formula for success With almost-daily headlines chronicling funding and scientific setbacks to the biotechnology industry, the challenges for scientist- entrepreneurs contemplating making a go of their idea seem daunting, even insurmountable. Yet biotech analysts, officials, researchers, and other observers insist that, despite the depressed financial climate in the industry and investor wariness, capital

Written byNeeraja Sankaran
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share


Industry observers maintain that capital is available for companies that have the right formula for success
With almost-daily headlines chronicling funding and scientific setbacks to the biotechnology industry, the challenges for scientist- entrepreneurs contemplating making a go of their idea seem daunting, even insurmountable.

Yet biotech analysts, officials, researchers, and other observers insist that, despite the depressed financial climate in the industry and investor wariness, capital should be available in 1995 for startups with the right formula for success. At the core of this mixture, they say, are sound ideas with high product potential, backed by a solid business plan and a management team that combines scientific savvy with entrepreneurial skills.

"The outlook for startups is surprisingly positive_the terms may be difficult when actually making a deal, but there's a lot more [start-up activity] going on than you would think," maintains Kenneth B. Lee, the national director of the life ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo